Rep. Josh Gottheimer Sells Novozymes A/S (OTCMKTS:NVZMY) Stock

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of Novozymes A/S (OTCMKTS:NVZMY). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novozymes A/S stock on June 1st. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Nintendo (OTCMKTS:NTDOY) on 6/17/2026.
• Sold $1,001 – $15,000 in shares of Insmed (NASDAQ:INSM) on 6/10/2026.
• Sold $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Booking (NASDAQ:BKNG) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 5/22/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 5/22/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 5/21/2026.

Novozymes A/S Stock Performance

Shares of NVZMY opened at $64.08 on Thursday. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $72.39. The stock has a market cap of $26.56 billion, a P/E ratio of 43.30, a PEG ratio of 1.22 and a beta of 0.92. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of $60.01 and a two-hundred day moving average of $60.39.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.31). The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%. As a group, research analysts predict that Novozymes A/S will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on NVZMY shares. Rothschild & Co Redburn raised Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Finally, Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Novozymes A/S has a consensus rating of “Buy”.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).